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CASE REPORT
HEMOPHAGOCYTIC SYNDROME ASSOCIATED WITH HEPATITIS A: CASE REPORT AND
LITERATURE REVIEW
Felipe Francisco TUON(1), Virginia Soares GOMES(1), Valdir Sabbaga AMATO(2), Maria Esther GRAF(1), Guilherme Henrique Hencklain FONSECA(3),
Carolina LAZARI(1) & Antonio Carlos NICODEMO(1)
SUMMARY
Virus-Associated Hemophagocytic Syndrome (VAHS) is a severe hematological disorder related to some viral infections. It is
an illness characterized by persistent fever, pancytopenia, splenomegaly, hyperferritinemia and, the most important,
hemophagocytosis observed in the bone marrow, liver and/or lymph nodes. VAHS associated with hepatitis A virus infection is
rarely described, despite the high incidence of this viral infection in the population in general. There is no consensus in the
literature regarding the optimal treatment of VAHS. In this article the clinical features, presumed pathogenesis, diagnostic criteria
and treatment of VAHS are discussed, including description of cases of VAHS related to hepatitis A virus infection found in the
medical literature.
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INTRODUCTION
Virus-Associated Hemophagocytic Syndrome (VAHS) is a severe
hematological disorder related to some viral infections8. Among these
viral infections, the most likely to be associated with VAHS are Epstein-
Barr virus, cytomegalovirus, human herpesvirus type 6 (HHV-6) and
HHV-810. Nevertheless, some reports have described the association
with human immunodeficiency virus (HIV), adenovirus, coxsackie
virus, measles, dengue, rubella, parvovirus B19, herpes simplex virus
and varicella zoster virus39. Moreover, some cases of hemophagocytic
syndrome have been reported in bacterial and protozoan infections16,21.
VAHS was described by RISDALL et al. in 1979. He associated
some hematological disorders with systemic viral infections in
immunosuppressed patients which had clinical criteria of
hemophagocytic syndrome36. These diagnostic criteria were later
reviewed by IMASHUKU and include persistent high fever, peripheral
blood cytopenia (two or more series), hyperferritinemia,
hyperlipidemia, and hemophagocytosis in the bone marrow
(hemophagocytic cell ratio over 3%), spleen and/or lymph nodes5. All
these diagnostic criteria should be present in a patient with an active
viral infection to confirm the diagnosis of VAHS15,17.
Hemophagocytic syndrome associated with hepatitis A virus
infection is rarely described, despite the high incidence of this infection
in the population in general4,7,9,32,33,42,47. There are only 12 cases reported
in the medical literature.
The purpose of this manuscript is to describe a case of hepatitis A
virus (HAV) infection, which developed into a VAHS and to review
the literature on this matter.
CASE REPORT
A 24-year-old woman was hospitalized for the first time on October
15, 2006, complaining of nausea, vomiting, myalgia, jaundice, asthenia
and fever. A diagnosis of acute hepatitis A was established based on
the presence of specific IgM antibody anti-HAV. She was discharged
from the hospital in better conditions. Thirty days later, all signs except
jaundice were improved and she was admitted to another hospital with
a diagnosis of severe anemia. Four blood units were transfused. After
ten days she became febrile again and was admitted at the Hospital
das Clinicas of University of São Paulo, Medical School.
The patient had presented severe jaundice and hepatosplenomegaly.
Initial and further laboratory data are described in Table 1. Serology
testing for toxoplasmosis, cytomegalovirus, rubella, EBV, hepatitis B
and C, HIV and HTLV I/II were negative. Autoimmune hepatitis
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antibodies were absent and the presence of IgM antibodies for hepatitis
A was confirmed.
Ten days after admission, the patient still had fever and several
blood units were required due to persistent severe anemia. A bone
marrow aspiration was performed and hemophagocytosis was then
diagnosed. Intravenous human immunoglobulin (IVIG) 400 mg/kg/day
was prescribed for five days. After that, she did not require any further
blood transfusion (Fig. 1). Despite the increased hemoglobin level,
the patient developed a neutropenia (600 cells/mm3) which was
successfully treated with G-CSF for three days. Three weeks later the
patient was discharged without any complaints. She was in good health
at the one year of follow-up.
DISCUSSION
The case here described has complied with all diagnostic criteria
and, as far as we know, it is the first case of hemophagocytic syndrome
associated with HAV infection in the Americas. Previous publications
came from Japan, Taiwan and one case from England, totalizing twelve
cases related to VAHS and HAV infection18,23,24,30,34,40,48,49. These
manuscripts were found in the medical literature online on the LILACS,
EMBASE, Web of Science and MEDLINE databases, including
references from selected studies and case series of VAHS19,41. Regarding
these cases, some epidemiological and laboratorial findings are
described in Table 2. Unfortunately, we were unable to describe three
cases because they were published in Japanese language.
Leukocyte count is either normal or slightly low in the HAV
infection and fever, in particular, rarely persists through the icteric
phase, unless in atypical cases or if complication occurred27,46.
Hyperferritinemia is described in HAV infection, but not higher than
5,000 ng/mL. Hypertriglyceridemia can occur in several infectious
diseases, including viral infections, but the levels usually do not exceed
500 mg/dL. Nevertheless, all previous clinical and laboratory features
are uncommon in a later phase of HAV infection. These findings and
hemophagocytosis in the bone marrow confirmed the diagnosis of
VAHS in the case reported here.
Table 2
Cases published of hepatitis A associated with hemophagocytic syndrome
Author/ Country Ref Age/ Comorbities Lukocytes Hb Platelets Date of ALT Total LDH Ferritin Bone
Year gender cells/µL (g/L) no. x103/µL cytopenia IU/L bilirubin IU/L ng/mL marrow
(after begin mg/L
symptoms)
Tuon 2006 Brazil - 24/F None 10,190 6 307 10 days 340 30.9 5,679 125,340 +
Watanabe 2002 Japan 15 45/M None 2,000 18.1 54 7 days 6,210 3.5 15,600 1,298 +
Watanabe 2002 Japan 15 41/M HCV 3,700 16.9 88 7 days 2,661 3.0 2,882 5,801 +
Tai 2005 Taiwan 16 32/M None 2,140 13.0 114 3 days 1,579 3.6 698 1,002 +
Wu 1995 Taiwan 17 23/M HCV 7,800 4.2 40 14 days 355 31 - - +
Onaga 2000 Japan 14 19/F None 2,800 14.9 97 4 days 11,510 4.0 20,210 66,096 +
Kyoda 1998 Japan 12 40/M None 5,800 15.9 37 admission 2,000 1.6 3,482 4,652 +
McPeake 1993 England 13 20/F Still’s 2,900 6.9 18 > 6 days 119 9 - - +
disease
Kondo 1995 Japan 11 49/F None 0,500 5.9 32 12 days 600 17 800 ? +
Ishii 2002 Japan 10 37/M Alcohol 6,000 13.8 10 21 days Normal 30 Normal ? +
abuse
 (Ref - reference; Hb - hemoglobin; ALT - alanine aminotransferase; LDH - lactate dehydrogenase; HCV - hepatitis C virus)
Table 1
Laboratory findings in a patient with VAHS and HAV
Laboratory finding 25/Oct. 16/Nov. 4/Dec.
Hemoglobin (g/L) 6 9.5 9.2
leukocytes (cells/µL) 10,190 4,570 4,311
Platelets (no. × 103/µL) 307 132 183
Direct bilirubin (mg/dL) 24.5 6.45 0.8
Indirect bilirubin (mg/dL) 6.43 1.33 0.7
AST (U/L) 451 112 71
ALT (U/L) 350 116 97
Ferritin (ng/mL) 125,340 16,780 6,542
Reticulocytes (%) 0.22 8.12 5.22
Triglycerides (mg/dL) 555 - 212
C-reactive Protein (mg/L) 66 24 11
Lactate dehidrogenase (U/L) 5,679 1,356 632
Fig. 1 - Level of hemoglobin following treatment of VAHS and HAV.
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Thrombocytopenia is the most common cytopenia in VAHS with
HAV infection, followed by leucopenia. Only one case presented anemia
in the literature reviewed. Some previous reports describe aplastic
anemia or pure red cell aplasia related to hepatitis A14,43. These and
other extrahepatic manifestations of HAV infection may be more
common in patients who have protracted disease, such as relapsing or
cholestatic hepatitis37,38. Cholestatic form of HAV infection is usually
characterized by marked jaundice, pruritus, fever, weight loss and
diarrhea. Biochemical and serologic abnormalities typically show high
levels of serum bilirubin and alkaline phosphatase, elevated serum
cholesterol, mild elevation of serum aminotransferases and often show
maintenance of the anti-HAV IgM. The symptoms and signs may last
for three months or more before complete recovery. This scenario is
similar to the case reported herein.
Neutropenia is found in these patients and it is a risk factor of
infections. Recent reports support the safety of Granulocyte-Colony
Stimulating Factor (G-CSF) in patients with VAHS and severe
neutropenia3,23,44,45. M-CSF is described as a trigger to the macrophage
activation, increasing hemophagocytosis and worsening cytopenia11,12,35.
The possibility of G-CSF to increase the macrophage activation is not
confirmed and it seems a useful drug to be used in patients with
neutropenia due to VAHS.
The physiopathology of VAHS is established in the phagocytosis
of blood cells precursors by macrophages2,22 (Fig. 2). KEREVEUR et
al. described increasing expression of MHC class I and II molecules
and increasing Macrophage-Colony Stimulating Factor (M-CSF)
receptor expression in the macrophages20. Phagocytosis of platelets
may be enhanced due to the presence of antiplatelet immunoglobulin
G. Nevertheless, WATANABE et al. verified the presence of
phagocytosis of platelets in the bone marrow48. Exaggerated activation
of this group of cells may be due to high levels of activated cytokines,
mainly of the inflammatory pattern. High levels of interferon-γ,
interleukin-2 receptor, tumor necrosis factor-α, interleukin-1 and
interleukin-6 have been demonstrated. This suggests that these
cytokines produced by the T-helper cells promote macrophages
activation31. The mechanism of abnormal cytokines production by these
“hyperactivated” T lymphocytes remains unclear. Some authors explain
this sustained activation by the persistence of antigens released by the
trigger infection. The maintenance of antigen expression can be an
innate immune defect found in natural killer cells46. Sometimes these
cells can not destroy the infected cell by inducing apoptosis due to
defect in the production of perforins or granzyme13,28. In the case
described herein, the persistent cholestasis of the HAV infection could
support this concept41.
The prognosis of the VAHS is mainly based in the severity and
duration of the cytopenias. Long-term neutropenia increases the risk
of severe infections, including gram-positive bacteria, such as S. aureus.
Thrombocytopenia should be cautiously observed because of the
possibility of spontaneous bleeding, which can occur in the central
nervous system as a fatal outcome. Anemia is a risk factor for infections
and can promote organ dysfunctions, such as heart failure and tissue
hypoxia. Despite of cytopenias, some cases of VAHS developed
disseminated intravascular coagulation and fatal organic dysfunction
due to severe sepsis, contributing to the mortality of more than 40% in
the largest series6.
The treatment of VAHS is not well defined because there are no
controlled studies, once this disease is not common48. The supportive
therapy consists of correcting the severe cytopenias and treating the
causal infection.
The specific action of IVIG in the treatment of VAHS is not well-
know26. LARROCHE et al. in France evaluated nine cases of VAHS
treated with IVIG and concluded that the treatment was effective and
reduced the time of hemophagocytosis25. However, more studies are
necessary to verify the real efficacy of IVIG in the treatment of VAHS.
Some authors consider the immunosuppressive therapy a base to control
hemophagocytosis. Although steroids have been commonly used in the
treatment of VAHS, several reports showed failure49. Pulse therapy with
steroid has showed improvement in some reports1. Plasmapheresis may
be an alternative therapy in order to improve symptoms and laboratory
abnormalities in the VAHS. Some reports have been successfully treated,
including some cases after high doses of corticoid therapy29.
More studies are necessary in order to clarify the physiopathology
and the immune mechanisms involved in this life-threatening disease.
RESUMO
Síndrome hemofagocitária associada com hepatite A: relato de
caso e revisão da literatura
A síndrome hemofagocitária associada a vírus é uma doença
hematológica grave relacionada com algumas síndromes virais. É
doença caracterizada por febre persistente, pancitopenia, espleno-
megalia, hiperferritinemia e hemofagocitose na medula óssea, fígado
e/ou linfonodos. A síndrome hemofagocitária associada ao vírus da
hepatite A é raramente descrita, apesar da alta incidência desta infecção
viral na população como um todo. Não existem consensos na literatura
a respeito do tratamento desta morbidade. Neste artigo, os aspectos
clínicos, patogênese, critérios diagnósticos e tratamento da síndrome
hemofagocitária associada a vírus, incluindo a descrição de casos
publicados da síndrome associada ao vírus da hepatite A.
Fig. 2 - Schema of viral associated hemophagocytic syndrome. (NK - Natural killer cell;
CD4+TL - Lymphocyte T CD4+; CD8+TL - Lymphocyte T CD8+; MO– - Macrophage, IL-1
- Interleukin-1; IL-2 - Interleukin-2; IFN-γ - Interferon gamma; TNF-α - Tumor necrosis
factor alpha.)
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